Logo-ps
Pharm Sci. 2024;30(3): 304-311.
doi: 10.34172/PS.2024.3
  Abstract View: 106
  PDF Download: 37

Research Article

Effects of Pentoxifylline on Inflammatory Factors and Quality of Life in Maintenance Hemodialysis Patients

Lachin Rezadoost 1 ORCID logo, Hamid Tayebi Khosroshahi 2, Farahnoosh Farnood 2, Parvin Sarbakhsh 3, Hossein behzad 1, Afshin Gharakhani 4,5* ORCID logo

1 Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Biostatistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
5 Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
*Corresponding Author: Email: anqarekhani@yahoo.com

Abstract

Background: Pentoxifylline has anti-inflammatory effects in end stage renal disease (ESRD) patients and may play an important role in reducing inflammatory factors and improving quality of life (QoL) in hemodialysis (HD) patients.

Methods: In this randomized placebo-controlled trial 88 chronic hemodialysis patients were divided into two groups with equal numbers. Intervention group received tablet pentoxifylline 400 milligrams and control group received the matching placebo, daily for 3 months. At baseline and after 3 months, inflammatory factors including serum levels of tumor necrosis factor-alpha (TNF-a) and C-reactive protein (CRP) were measured. Also, the Medical Outcome Study 36-Item Short-Form Health Survey (SF-36) quality of life (QoL) questionnaire was completed by each patient at the beginning and end of the study.

Results: Significant reduction in serum levels of TNF-a, CRP as well as substantial improvement of all dimensions of QoL were observed in intervention group after 3 months of pentoxifylline treatment (P = 0.04; P <0.001, P <0.05 respectively). Between groups comparison showed marked reduction in inflammatory markers including TNF-a and CRP in recipients of pentoxifylline than control group at the end of the study (P = 0.003 for both). In addition to dimensions of physical component score (PCS), mental component score (MCS) and overall score of QoL showed significant improvement in the pentoxifylline group compared to the placebo group at month 3 of the study (P = 0.003; P = 0.027, P = 0.002 respectively).

Conclusion: Use of pentoxifylline in HD patients illustrated positive effects on inflammation and health-related QoL.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 103

Your browser does not support the canvas element.


PDF Download: 37

Your browser does not support the canvas element.

Submitted: 17 Sep 2023
Revision: 17 Jan 2024
Accepted: 19 Jan 2024
ePublished: 06 Apr 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)